Wuhan Kangfude Biotechnology

Comfort Biopharma is a clinical-stage biotechnology company headquartered in Wuhan, China, dedicated to developing first-in-class and best-in-class treatments for metabolic and renal diseases. The company's primary focus is on conditions such as hyperoxaluria, kidney stones, and gout, which affect millions of patients worldwide. Its lead program, KFD-101, is an orally administered recombinant oxalate decarboxylase currently in Phase 2 clinical trials for the treatment of primary and enteric hyperoxaluria. Beyond its enzyme therapy pipeline, the company is also developing small molecule inhibitors targeting URAT1 for hyperuricemia. Comfort Biopharma leverages a robust protein engineering platform to create stable and effective therapeutic enzymes. The company was founded by industry veterans with extensive experience in global pharmaceutical development.